|
China-TI-TI Azienda Directories
|
Azienda News:
- 7 FDA-Approved CAR T-Cell Therapies Advancing Cancer Treatment
According to BCC Research, the global market for CAR T-cell therapy is expected to increase significantly In 2024, it was valued at approximately $4 6 billion and is projected to reach $25 1 billion by the end of 2029, growing at a compound annual growth rate (CAGR) of 40 2%
- FDA-Approved CAR T-Cell Therapy List: Complete Guide 2024
Discover the complete FDA-approved CAR T-cell therapy list with detailed treatment options, success rates, and approved indications for cancer patients Updated for 2024
- 2024 Year End Overview: Developments in CAR T-Cell Therapy
In early November 2024, the Food and Drug Administration (FDA) approved Autolus Inc ’s CAR T-cell therapy obecabtagene autoleucel (Aucatzyl) for the treatment of relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL) Aucatzyl is a CD19-directed genetically modified autologous T cell immunotherapy
- Overview of approved CAR-T products and utility in clinical practice
Irrespective of side effects, CAR T-cells have expanded the therapies available for relapsed and refractory hematologic malignancies and significantly improved patient outcomes Below, we review the currently commercially available CAR T-cell products and their indications as of 2023 Table 1
- A Review of CAR T Cells and Adoptive T-Cell Therapies in . . . - PubMed
As of December 2024, the US Food and Drug Administration (FDA) approved six CAR T-cell therapies, with ten CAR T-cell therapies commercially available globally, which target the CD19 and B-cell maturation antigen (BCMA) molecules and with approved indications that include B-cell acute lymphoblastic leukemia (ALL), large B-cell lymphoma (LBCL
- FDA’s Recent Approval of 2 CAR T-Cell Therapies a ‘Big Step Toward . . .
Rye Brook, N Y , April 16, 2024 – The U S Food and Drug Administration (FDA) recently approved the CAR T-cell therapies ciltacabtagene autoleucel (cilta-cel; Carvykti™) and idecabtagene vicleucel (ide-cel; Abecma®) for earlier treatment of adults with multiple myeloma
- FDA Approved New CAR-T, Earlier Lines of Treatment in Other Similar Ag
Chimeric antigen receptor T cell (CAR-T) therapies had quite the year in 2024, with the first approval of a new agent in nearly three years, as well as a handful of expanded indications, including two that moved the moved the agents into an earlier line of treatment
- Recent Trends of CAR-T Cell Therapies for Cancer Treatment
Off-the-shelf CAR-T cell therapies, leaner manufacturing processes, and combination therapy with mRNA vaccines, oncolytic viruses, and insertable bio-scaffolds are promising developments to make CAR-T cell therapy more clinically meaningful, widely available, and affordable in the future
- The next-generation CAR-T therapy landscape - Nature
Chimeric antigen receptor (CAR)-T cell therapies are becoming established as an important treatment modality for cancer Following the pioneering approval of the CD19-targeted CAR-T therapy
- FDA approves new CAR-T competitor to Gilead’s Tecartus
The Food and Drug Administration on Friday approved a new cell therapy for a type of leukemia Called Aucatzyl, the CAR-T was developed by U K -based Autolus Therapeutics to treat people with B-cell precursor acute lymphoblastic leukemia whose disease has progressed following treatment with chemotherapy and other medicines
|
|